Background: Lung Cancer Screening (LCS) is an evolving field with variations in its implementation in various countries. There are only scarce data from National LCS programs. Aim: We aim to provide an up-to-date overview of the current evidence regarding the use of biomarkers in LCS. Materials and Methods: A multidisciplinary Task Force experts’ panel collaborated and conducted a systematic literature search, followed by screening, review and synthesis of available evidence. Results: Biomarkers in LCS could be used to improve risk stratification in high-risk participants, improve clarification regarding indeterminate lung nodules and avoid overdiagnosis in suspicious lung findings. Currently, there seem to be promising biomarkers (blood/serum/breath) that have been studied in various trials; however, there is still a lack of solid evidence in clinical validation that would pave the way for their integration into LCS programs. Conclusions: Biomarkers are the next logical step in improving the LCS pathway and its efficiency by playing an adjuvant role in a minimally invasive way. National LCS programs and pilot studies should integrate biomarkers to validate their accuracy in real-life LCS participants.
背景：肺癌筛查（LCS）是一个不断发展的领域，各国在实施中存在差异。目前来自国家层面LCS项目的数据仍较为匮乏。目的：本文旨在提供关于生物标志物在LCS中应用的最新证据综述。材料与方法：由多学科专家组成的工作组通过系统文献检索，对现有证据进行筛选、评估与整合分析。结果：LCS中的生物标志物可用于改善高危人群的风险分层、辅助评估性质不明的肺结节，并避免对可疑肺部发现的过度诊断。目前多项试验中已出现具有潜力的生物标志物（血液/血清/呼气检测），但其临床验证仍缺乏坚实证据，尚未达到整合至LCS项目的成熟阶段。结论：生物标志物作为微创辅助手段，是优化LCS路径与提升筛查效率的重要发展方向。国家层面的LCS项目及试点研究应纳入生物标志物验证，以评估其在真实筛查人群中的准确性。
肿瘤(癌症)患者之家